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Calcium/calmodulin (Ca2+/CaM) dependent protein kinase II (CaMKII) has emerged as a key
nodal protein in the regulation of cardiac physiology and pathology. Due to the particularly
elegant relationship between the structure and function of the kinase, CaMKII is able to
translate a diverse set of signaling events into downstream physiological effects. While
CaMKII is typically autoinhibited at basal conditions, prolonged rapid Ca2+ cycling can
activate the kinase and allow post-translational modiﬁcations that depend critically on the
biochemical environment of the heart.Thesemodiﬁcations result in sustained, autonomous
CaMKII activation and have been associated with pathological cardiac signaling. Indeed,
improved understanding of CaMKII activation mechanisms could potentially lead to new
clinical therapies for the treatment or prevention of cardiovascular disease. Here we review
the knownmechanisms of CaMKII activation and discuss some of the pathological signaling
pathways in which they play a role.
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CaMKII STRUCTURE/FUNCTION RELATIONSHIP
Calcium/calmodulin (Ca2+/CaM) dependent protein kinase II
(CaMKII) is expressed as a multimeric protein, typically com-
prised of 12 subunits in most commonly observed physiological
conditions (Hoelz et al., 2003). Individual monomers assemble
into a dodecameric mulitmer via association at the C-terminal
domain of each subunit. This association takes the form of a pair
of hexameric rings arranged in parallel with one another (Rellos
et al., 2010). This CaMKII structural motif is sometimes termed
a “wagon wheel” arrangement, as individual monomers form the
spokes of the wheel around a central core.
Eachmonomer is itself comprised of three domains (Figure 1).
The C-terminal association domain directs assembly of the
CaMKII multimer, while the N-terminal catalytic domain binds
to potential substrates and performs the serine/threonine kinase
function of CaMKII. In the intervening linker region (the com-
position of which varies greatly depending on isoform and splice
variant) lies the regulatory domain, which has two primary roles.
First, the regulatory domain acts as a substrate for the catalytic
domain within each CaMKII monomer, while adjacent regula-
tory domains within the multimer block both substrate and ATP
binding to the catalytic domain itself (Rosenberg et al., 2005).
Thus, the regulatory and catalytic domains are tightly associated
at basal conditions, resulting in autoinhibition of the kinase. Sec-
ondly, the regulatory domain binds CaM with a KD of 10–70 nM
(Gaertner et al., 2004) when intracellular [Ca2+] is elevated (half
maximal CaM occupancy requires approximately 1.0 μM Ca2+;
Rostas and Dunkley, 1992). When CaM binds to CaMKII, a con-
formational shift occurs that disrupts the association between the
catalytic and regulatory domains, exposing the catalytic domain
for substrate binding and relieving autoinhibition of the kinase.
CaMKII function is critically linked to this CaM binding func-
tion of the regulatory domain; indeed, all known mechanisms
of CaMKII activation require Ca2+/CaM binding as an initiat-
ing step. Thus, the extent of CaMKII activation within a cell
is likely to be at least partly dependent on local CaM concen-
trations, as has been proposed in cardiac myocytes (Saucerman
and Bers, 2008). The role of the regulatory domain to CaMKII
function is so integral, it is not surprising to discover that the
known isoforms and splice variants of mammalian CaMKII have
nearly identical primary structure within the regulatory domain
(Figure 2).
CaMKII PHOSPHORYLATION AND AUTONOMOUS ACTIVITY
The duration of CaMKII activation by Ca2+/CaM binding is
dependent on the frequency of Ca2+ release events (De Koninck
and Schulman, 1998). Conditions of prolongedCa2+/CaMassoci-
ation with CaMKII, as would be observed during lengthy or high
frequency calcium transients, allow for intersubunit autophos-
phorylation of CaMKII monomers at the T287 (T286 in the α
isoform) site. The addition of a phosphate group at T287 has
two critical effects on CaMKII function. First, the binding of
afﬁnity of CaM for the CaMKII regulatory domain increases
by more than 1000-fold (Meyer et al., 1992). Second, the pres-
ence of a negatively charged phosphate group at the T287 site
precludes reassociation of the catalytic and regulatory domains,
preventing autoinhibion even if [Ca2+]i falls and CaM dissoci-
ates from CaMKII (Lai et al., 1987). Subsequently, autonomous
activation of CaMKII by T287 phosphorylation will persist until
the phosphate group is removed by a protein phosphatase (PP1 or
PP2A; Stack et al., 1997). The extent of CaMKII activation in the
heart after autophosphorylation is not known, though evidence
in the neuronal form of CaMKII points to autonomous activ-
ity that corresponded to less than 25% of full CaMKII activity
(Coultrap et al., 2010).
CaMKII has been called the “memory molecule” in part for
its function in the processing of neural information from short-
term to long-term memory, but also due to the ability of CaMKII
to translate Ca2+ transient frequency into autonomous activa-
tion of the kinase (Hudmon and Schulman, 2002; Coultrap and
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FIGURE 1 | Schematic representation of the CaMKII structure/function
relationship in the heart. Under basal conditions, the kinase is
autoinhibited due to interaction between the regulatory and catalytic
domains. Direct activation occurs when Ca2+/CaM binds to CaMKII, while
subsequent post-translational modiﬁcation (PTM) results in autonomous
kinase activity. Protein interactions with CaMKII autonomously activate
CaMKII in the brain but have not yet been demonstrated in the heart. Note
that the size of each region is not to scale and will vary by isoform and
splice variant of CaMKII.
FIGURE 2 | Alignment of the primary structure of regulatory domains
from Mus musculus CaMKII isoforms. Speciﬁc residues associated with
autonomous activation by post-translational modiﬁcations have been
labeled.
Bayer, 2012). Indeed, the discovery that post-translational mod-
iﬁcation of CaMKII resulted in a shift from Ca2+-dependent
to Ca2+-independent states gave rise to the now popular belief
that CaMKII functions as a nodal cardiac signaling molecule that
translates upstream cellular events into downstream physiological
effects. In the heart, autophosphorylation of CaMKII is partic-
ularly prevalent during β-adrenergic signaling (Erickson et al.,
2011) and is thought to play a key role in the development of
cardiac hypertrophy and dilated cardiomyopathy (Zhang et al.,
2003).
CaMKII OXIDATION
While direct Ca2+/CaM-binding and T287 autophosphoryla-
tion have been recognized for over two decades, more recently
published results have demonstrated new pathways of CaMKII
activation. For example, CaMKII can be directly modiﬁed by reac-
tive oxygen species (ROS), resulting in autonomous activation
(Erickson et al., 2008). The regulatory domain of CaMKII con-
tains a pair of redox-sensitive amino acids (C280/M281 in the
α isoform, M281/M282 in the β, γ, and δ isoforms) that can
be oxidized when exposed to elevated levels of oxidative stress.
As is the case in T287 phosphorylation, redox modiﬁcation of
CaMKII only occurs after Ca2+/CaM binding initiates a con-
formational shift of the inhibited kinase and exposes the target
sites. An examination of the crystal structure of CaMKII sug-
gests that the addition of an oxidative modiﬁcation at the M282
site preserves kinase activity by preventing reassociation between
the regulatory and catalytic domains (Rellos et al., 2010). Addi-
tionally, this study suggests that M282 oxidation should preclude
T287 phosphorylation, though this hypothesis has not been con-
ﬁrmed experimentally. Mutation of the M281 and M282 residues
does not disrupt phosphorylation-dependent CaMKII activation
(Erickson et al., 2008). We can therefore conclude that while
the phosphorylation- andoxidation-dependentmechanisms share
similarities, they constitute parallel pathways for maintaining
CaMKII activation.
Since the redox-dependentmechanismwas reported, oxidation
of CaMKII has been found to play a role in a number of car-
diac pathologies. For example, the renin-angiotensin-aldosterone
signaling (RAAS) pathway promotes enhanced oxidative stress
in the heart. Angiotensin II (AngII) induced apoptosis of car-
diac myocytes is ablated in isolated neonatal mouse myocytes
expressing the oxidant-resistant mutant of CaMKII (Erickson
et al., 2008). Similarly, elevated levels of circulating aldosterone
enhance CaMKII oxidation, leading to apoptosis, impaired car-
diac function, and potential cardiac rupture (He et al., 2011; Velez
Rueda et al., 2012). Redox-dependent CaMKII activation also
enhances electrical remodeling in the heart, including enhanced
Na+ current (and subsequent [Na+]i overload; Wagner et al.,
2011), apoptosis of sinoatrial nodal cells (Swaminathan et al.,
2011), and eventual impaired conduction of transients (Chris-
tensen et al., 2009), all of which contribute to life-threatening
arrhythmias. Moreover, a diabetic mouse model expressing oxi-
dation resistant CaMKII (MM281/282VV) was found to be
resistant to sinoatrial nodal cell death, ﬁbrosis, and mor-
tality after myocardial infarction compared to diabetic ani-
mals expressing wild type CaMKII (Luo et al., 2013). These
observations suggest that oxidation-dependent CaMKII activity
plays a critical role in numerous pathological processes in the
heart.
Just as T287 phosphorylation of CaMKII is reversed by phos-
phatases, the enzyme methionine sulfoxide reductase A (MsrA)
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reduces oxidized methionine residues to inactivate the kinase
(Erickson et al., 2008). Thus, MsrA has emerged as a poten-
tial cardioprotective molecule against the deleterious effects of
oxidative stress. For example, a genetic knockout mouse model
lacking MsrA was found to have signiﬁcantly increased redox-
activated CaMKII, myocyte apoptosis, structural remodeling,
and mortality 4 weeks after myocardial infarction compared
to wild type littermates (Erickson et al., 2008). Conversely, a
transgenic mouse model that overexpresses MsrA was found
to be less susceptible to aldosterone-mediated CaMKII oxida-
tion and cardiac remodeling (He et al., 2011), and was also
more resistant to AngII-induced atrial ﬁbrillation (Purohit et al.,
2013). Interestingly, the expression and activity of MsrA is
reduced in brain tissue from aging human patients (Petropou-
los et al., 2001), and this age-dependent reduction in MsrA
activity is linked with the development of Alzheimer’s dis-
ease (Gabbita et al., 1999). However, the age-dependence of
MsrA expression and activity in the human heart has not been
studied.
CaMKII ACTIVATION IN DIABETES
Diabetes mellitus is marked by a number of altered cellu-
lar signaling pathways, creating physiological stress that can
activate CaMKII. For example, diabetic patients have a signif-
icantly greater proportion of oxidized to total CaMKII com-
pared to non-diabetic patients (Luo et al., 2013), consistent
with observations that altered cellular metabolism in diabet-
ics results in enhanced oxidative stress. A recently published
study points to a novel mechanism for CaMKII activation dur-
ing hyperglycemia and diabetes through the addition of an
O-linked N-acetylglucosamine (O-GlcNAc) modiﬁcation (Erick-
son et al., 2013). Post-translational modiﬁcation by O-GlcNAc
(“O-GlcNAcylation”) is an emerging ﬁeld with important reg-
ulatory implications in disease states characterized by altered
glucose signaling, such asmyocardial infarction anddiabetes (Hart
et al., 2007; Chatham and Marchase, 2010). O-GlcNAc modiﬁ-
cation can alter protein function (Dias et al., 2009), and such
regulation is known to play a role in both the heart and brain
(Gao et al., 2001). O-GlcNAcylation is catalyzed by the enzyme
O-GlcNAc transferase in the presence of the substrate UDP-N-
acetylglucosamine, which is produced in conditions of elevated
glucose as a product of the hexosamine biosynthesis pathway (Hart
et al., 2007).
When CaMKII is activated by Ca2+/CaM binding in the pres-
ence of elevated [glucose], an O-GlcNAc modiﬁcation is added to
the regulatory domain at S280 (S279 in the alpha form), resulting
in autonomous activation of the kinase (Erickson et al., 2013). The
extent of both O-GlcNAc modiﬁcation and activation of CaMKII
varies with glucose availability in a dose-dependent manner and is
reversible by the action of O-GlcNAcase, an enzyme that removes
O-GlcNAcmodiﬁcations from proteins. These observations point
to a potential regulatory role for O-GlcNAcylation of CaMKII,
consistent with the observation that the ratio of O-GlcNAc modi-
ﬁed CaMKII to total CaMKII is greatly enhanced in the heart and
brain from diabetic patients. Further, glucose induced Ca2+ leak
from the sarcoplasmic reticulum (measured as Ca2+ sparks) is
both CaMKII and O-GlcNAc dependent, suggesting a connection
between O-GlcNAc mediated CaMKII activity and arrhythmoge-
nesis in the diabetic heart. Indeed, pharmacological inhibition of
the hexosamine biosynthesis pathway (and therefore the produc-
tion of O-GlcNAc precursors) prevented ventricular tachycardia
in hearts from diabetic rats challenged with dobutamine and caf-
feine (Erickson et al., 2013). Taken together, these observations
suggest that O-GlcNAc modiﬁcation of CaMKII could play a crit-
ical role in structural and electrical remodeling in the diabetic
heart.
ALTERNATE MECHANISMS OF CaMKII ACTIVATION IN THE
HEART
The preceding sections describe several established mechanisms
of CaMKII activation in the heart, but it is unlikely that they are
exhaustive. Indeed, emerging evidence points to other potential
mechanisms that are not fully described for cardiac CaMKII. For
example, several recent studies have provided new evidence sug-
gesting the existence of an undescribed mechanism of CaMKII
activation mediated by intracellular nitric oxide (NO). For exam-
ple, isoproterenol-induced Ca2+ leak from the sarcoplasmic
reticulum is determined in part by the activity of both NO syn-
thase and CaMKII (Curran et al., 2009). ATP-sensitive potassium
channels are also modulated by NO, and these NO-dependent
effects on KATP were ablated in knockout mice lacking the car-
diac isoform of CaMKII (Zhang et al., 2013). CaMKII activity
is enhanced in the presence of the NO donors NOC-18 (Zhang
et al., 2013) and GSNO [Gutierrez et al., 2013; though another
study found inactivation of CaMKII by NO donors (Song et al.,
2008)], while a non-site speciﬁc antibody suggests that, at least in
vitro, CaMKII contains S-nitrosylated cysteine residues. Compu-
tational prediction of S-nitrosylation sites on CaMKII indicate
three potential target sites, including the C290 site present in
the regulatory domain (Gutierrez et al., 2013). While none of the
potential sites have been conﬁrmed and the mechanism by which
nitrosylation induces CaMKII activity has not been described, the
evidence in favor of this novel pathway of CaMKII activation is
compelling.
Additional potential mechanism for activation of CaMKII in
the heart is through interaction of the kinasewith protein partners.
Theﬁrst andbest described suchmechanismwas identiﬁed in theα
(neuronal) isoform of CaMKII, which can become autonomously
activated through association with the NMDA receptor (Strack
and Colbran, 1998; Bayer et al., 2001), contributing to long term
potentiation (Barria and Malinow, 2005), and memory consol-
idation (Halt et al., 2012). While this topic extends beyond the
scope of the current, cardiac-focused review [please see refer-
ences Coultrap and Bayer (2012) and Colbran (2004) for a closer
examination of CaMKII/NMDA receptor binding], it does sug-
gest the possibility that interactions between CaMKII and other
protein partners could alter kinase activity. For example, binding
of α-actinin to the α isoform of CaMKII can mimic Ca2+/CaM
binding and activate the kinase in HEK293 cells (Jalan-Sakrikar
et al., 2012). In cardiac cells, CaMKII association with the KV4.3
potassium channel blocks Ca2+/CaM binding and reduces kinase
activity (Keskanokwong et al., 2011), but whether protein binding
can enhance CaMKII activity in the heart is an important open
question.
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SYNERGISTIC ACTIVATION OF CaMKII: AN OPEN QUESTION
While our understanding of the underlying mechanisms that
determine CaMKII function has grown rapidly of late, numer-
ous questions remain unanswered. Recent efforts have focused
on the characterization of individual pathways of CaMKII acti-
vation and on the downstream pathological consequences of
these speciﬁc pathways. In the context of cardiac disease states
with complex pathophysiologies, such as in heart failure or
diabetes, multiple signaling pathways are likely to be altered.
Complicating matters is the issue that the various pharmaco-
logical inhibitors of CaMKII currently in use rely on different
mechanisms. For example, the CaMKII inhibitor KN-93 (but
not the inactive analog KN-92) competes with CaM binding
to the CaMKII regulatory domain and prevents activation of
the kinase (Hudmon and Schulman, 2002). However, KN-93
has no such CaMKII inhibitory effect after autonomous activa-
tion (Buard et al., 2010). Conversely, peptide inhibitors such as
AIP and AC3-I, which mimic the regulatory domain sequence
and bind to the catalytic domain of CaMKII, prevent substrate
binding regardless of the mode of CaMKII activation. Thus,
careful consideration must be given to the selection and develop-
ment of inhibitors in studies focused on CaMKII (Coultrap and
Bayer, 2011). For a more thorough review of CaMKII inhibitors,
please see the review by Dr. Howard Schulman in this Research
Topic.
Moreover, CaMKII itself contributes to the regulation of intra-
cellular signaling processes such asmitochondrial function (Joiner
et al., 2012) and insulin secretion (Dixit et al., 2013), many of
which could form potential feedback loops through additional
CaMKII modiﬁcation. Thus, the interplay between various mech-
anisms of CaMKII activation, particularly during the development
of cardiovascular diseases, is an important open line of inquiry.
Moreover, models based on data generated from examination
of the crystal structure of CaMKII predict that intersubunit
phosphorylation does not occur as a random, coincidence-
based process, but rather occurs via cooperative modiﬁcation of
individual subunits (Chao et al., 2010). This observation sug-
gests that the activity of each CaMKII monomer is mediated
acutely by the post-translationalmodiﬁcations present on adjacent
monomers.
Does the presence of one type of modiﬁcation enhance the
probability of other modiﬁcations occurring on the same or
on neighboring subunits? In one study enhanced O-GlcNAc
modiﬁcation of CaMKII was associated with an increase in phos-
phorylation of CaMKII in isolated rat myocytes exposed to
hyperglycemia (Erickson et al., 2013). In summary, these results
provide compelling evidence for potential cross-talk between sig-
naling mechanisms, but more work will be required to elucidate a
fully integrative model of CaMKII activation.
CONCLUSION
Calcium/calmodulin dependent protein kinase II activity is depen-
dent on a number of intracellular signaling pathways, either
independently or as part of an integrative system. Thus, CaMKII
represents an important nodal point in the translation of a broad
range of cellular stresses into physiological and pathological path-
ways in the heart and other organ systems. Consequently, CaMKII
has emerged as a potential therapeutic target in the clinical treat-
ment of cardiac and neurological diseases. If we hope to develop a
new generation of therapies based on modulation of CaMKII, we
must understand the mechanisms that regulate CaMKII activity.
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